MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
TG Therapeutics Operating Expenses 2011-2026 | TGTX
Annual Operating Expenses TG Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 196 M | - | 274 M | 169 M | 175 M | 119 M | 79.1 M | 63.3 M | 55.9 M | 20.3 M | 25.8 M | 882 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 274 M | 882 K | 107 M |
Quarterly Operating Expenses TG Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 60.7 M | 44.8 M | - | 35.1 M | 39.5 M | 68.9 M | - | 87.2 M | 79 M | 90 M | - | 85.8 M | 50.9 M | 50.3 M | 38 M | 60.9 M | 35.6 M | 34.7 M | 54.2 M | 34.4 M | 44.4 M | 41.6 M | 31.1 M | 31.6 M | 28.5 M | 27.7 M | 24.1 M | 25 M | 16.1 M | 14 M | 17.7 M | 13.9 M | 17.1 M | 14.6 M | 18.8 M | 17.5 M | 12 M | 7.64 M | - | 4.69 M | 6.67 M | 3.75 M | - | 2.71 M | 3.1 M | 17.4 M | - | 30.1 K | 297 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90 M | 30.1 K | 32.4 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.45 | -7.94 % | $ 170 M |  USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Compugen Ltd.
CGEN
|
32.2 M | $ 2.1 | -5.41 % | $ 196 M |  Israel |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Alpine Immune Sciences
ALPN
|
103 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
55.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
512 M | $ 88.08 | -1.69 % | $ 21.3 B | Germany |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 51.84 | -8.97 % | $ 4.66 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 28.62 | -4.38 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.48 | -2.1 % | $ 208 M | USA |
 |
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.09 | -2.22 % | $ 5.09 M | Israel |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.23 | -3.28 % | $ 2.7 B | USA |